Fortress Biotech Investigated by the Portnoy Law Firm

Core Viewpoint - Fortress Biotech Inc. is under investigation for possible securities fraud following a significant stock price drop after the FDA issued a Complete Response Letter regarding its New Drug Application for CUTX-101, citing manufacturing deficiencies [3]. Group 1: Legal Actions - The Portnoy Law Firm has initiated an investigation into Fortress Biotech Inc. and may file a class action on behalf of investors [1]. - Investors are encouraged to contact the Portnoy Law Firm to discuss their legal rights and options for pursuing claims to recover losses [2]. Group 2: Company Developments - On October 1, 2025, Fortress Biotech and its subsidiary, Cyprium Therapeutics, announced the FDA's Complete Response Letter related to CUTX-101, which noted cGMP deficiencies at the manufacturing facility [3]. - Following the announcement of the CRL, the stock price of Fortress Biotech experienced a decline [3].